DNX 2440
Alternative Names: Delta-24-RGDOX; DNX-2440Latest Information Update: 28 Apr 2025
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer DNAtrix; University of Navarra
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; OX40 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma; Liver metastases
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in Spain (Intratumoural, Injection)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Liver metastases in USA (Intratumoural, Injection)
- 09 Apr 2024 DNAtrix terminates a Phase-I clinical trials in Liver metastases in USA (Intratumoural) due to management decision (NCT04714983)